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Abstract 
Objectives: In grade III-IV breast cancer, dissemination of disease needs to be assessed. Until now 
this was done by conventional imaging (liver ultrasonography, chest X-ray and bone scintigraphy), 
but evidence favoring the use of FDG-PET/CT is accumulating. Methods: Patients with high-risk 
breast cancer, who had received conventional imaging and FDG-PET/CT, were included. Patients 
were staged and assigned a treatment after 1) conventional imaging and 2) FDG-PET/CT, both by a 
multidisciplinary oncology team. Equivocal FDG-PET/CT findings were histologically confirmed. 
Results: 16 patients were included (mean age 59 years). TNM-stage changed in 5 patients (31%) 
after FDG-PET/CT. In 3 patients (19%) unknown distant metastases were detected by FDG-PET/CT. 
An adjustment of treatment took place in 4 patients (25%). Conclusions: Our case series empha- 
sizes the role of FDG-PET/CT in the staging of high-risk breast carcinoma, especially in the assess- 
ment of distant metastases. We suggest replacing conventional imaging with FDG-PET/CT. 
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1. Introduction 
Annually, 364.000 (or 109 per 100.000) patients are diagnosed with breast cancer in the European Union [1]. 
Either discovered by mammography screening or through self-examination, in case of a suspicious lesion pa- 
tients are referred to a radiologist to undergo an ultrasonography with histological confirmation. When this re- 
veals breast cancer, patients are staged according to the TNM-classification and are stratified into a low-risk 
(stage I and II) and high-risk group (stage III and IV).  
In Europe, it is common practice to assess dissemination of disease in grade III-IV breast cancer. Until now, 
conventional imaging with liver ultrasonography, chest X-ray and bone scintigraphy has been used for this pur- 
pose [2]. However, the sensitivity and specificity of these methods are relatively low [2]-[4], while treatment 
choice is still based on the results of these tests. Therefore, new modalities with higher sensitivity and specificity 
in the detection of metastases are needed.  
Recently, the Dutch Guidelines for breast carcinoma, developed by NABON, emphasized the relatively new 
role of (18)-fluorodeoxyglucosis positron emission tomography/computed tomography (FDG-PET/CT) in breast 
carcinoma staging [5]. After extensive literature study they conclude that patients with a TNM-stage of III are 
entitled to an FDG-PET/CT because of the better results in detecting metastases. Furthermore, they recommend 
considering an FDG-PET/CT in stage II primary breast carcinoma and when local recurrent or metastatic disease 
is suspected. Unfortunately, clinicians still hesitate to implement FDG-PET/CT in the standard care of these pa- 
tients.  
To demonstrate that FDG-PET/CT can change clinical stage and influence treatment decisions, this short pa- 
tient series was conducted to compare staging and treatment choices based either on conventional imaging or 
FDG-PET/CT. 
2. Materials and Methods 
From August 2007 till August 2013, all patients with high risk breast cancer were retrospectively included in the 
present study when conventional imaging as well as FDG-PET/CT was consecutively performed within 3 
months. Conventional imaging consisted of liver ultrasonography, chest X-ray and bone scintigraphy. Liver ul- 
trasonography and chest X-ray were performed routinely. The procedures were assessed by experienced radiol- 
ogists. The bone scintigram was performed 3 hours after intravenous injection of 500 - 600 MBq of Technetium- 
99m-hydroxymethane-diphosphonate. Whole body images from anterior and posterior were obtained simulta- 
neously by a dual-head gamma camera (Symbia T, Siemens Healthcare). The bone scan was assessed by an ex- 
perienced nuclear medicine physician. 
Whole-body PET/CT images were obtained with an integrated 40-MDCT PET/CT scanner (Biograph 40 True 
Point PET/CT, Siemens Healthcare). Patients fasted for 6 hours before intravenous injection of 3 MBq/kg body 
weight FDG. Before injection of FDG, blood glucose levels were confirmed to be <11 mmol/L (i.e. <198 
mg/dL). Incubation was performed in a warm room with patients in supine position. Sixty minutes after FDG 
injection, image acquisition was performed. First, low-dose, unenhanced CT images were acquired with the fol- 
lowing parameters: 120 kV, 26 - 30 mAs (automatic dose modulation), 0.8-second tube rotation time, pitch of 
1.2, and 1.5-mm slice width (reconstructed to contiguous 5-mm axial slices to match section thickness of the 
PET images). PET-scanning from midfemur to the base of the skull was performed in five or six bed positions, 3 
minutes per bed position. Low-dose CT data was used for attenuation correction of the PET images, which were 
reconstructed with an ordered-subsets expectation maximization algorithm for 14 subsets and four iterations. 
The image reconstruction matrix was 128 × 128. FDG-PET/CTs were assessed by an experienced nuclear medi- 
cine physician.   
Disease staging and treatment regimen were formulated by a multidisciplinary oncology team in two sessions 
based on 1) conventional imaging and 2) FDG-PET/CT. The oncology team consisted of 1 - 2 medical oncolo- 
gists, an oncologic surgeon, a radiotherapist, a nuclear medicine physician and a radiologist, all with experience 
in the field of breast carcinoma. When lesions on FDG-/PET-CT were equivocal, histology was obtained to re- 
veal the final diagnosis. Afterwards, staging and treatment adjustments were reviewed by one of the authors 
(BB). 
3. Results 
Sixteen patients with high-risk breast carcinoma were included in the study, with a mean age of 59 years (range 
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33 - 84). The time between conventional and FDG-PET/CT imaging was less than 1 month in 13 cases, 2 
months in 2 cases and 3 months in 1 case. The stage of disease after conventional imaging and before FDG- 
PET/CT was IIIA in 4 patients (25%), IIIB in 3 patients (19%), IIIC in 2 patients (13%) and IV in 7 patients 
(44%). After FDG-PET/CT the stage of disease was IIIA in 4 patients, IIIB in 1 patient (6%), IIIC in 2 patients 
and IV in 9 patients (56%). In 5/16 patients (31%) TNM-stage changed after FDG-PET/CT: in 4/5 patients this 
resulted in upstaging of disease, in 1/5 patients in down staging. Examples of these cases are depicted in Figure 
1 and Figure 2. In 3 patients (19%) distant metastases were diagnosed after FDG-PET/CT, while conventional 
imaging did not identify them. Details of TNM-stage changes are described in Table 1. 
After conventional imaging, 8/16 (50%) patients were planned to undergo (neo)-adjuvant chemotherapy and 
radiotherapy, followed by surgery. 7 patients (44%) were assigned to palliative chemotherapy and 1 to locore- 
gional radiotherapy. After FDG-PET/CT 7/16 patients (44%) were treated with (neo)-adjuvant chemotherapy 
and radiotherapy with surgery, 8/16 (50%) palliative chemotherapy and 1 locoregional radiotherapy. In 4 pa- 
tients (25%) a treatment adjustment was induced by FDG-PET/CT results: 2 patients changed from adjuvant 
chemotherapy and radiotherapy plus surgery to palliative chemotherapy and 1 patient changed vice versa. In 1 
patient (no. 3), the field of adjuvant radiotherapy changed due to FDG-PET/CT. All treatment changes took 
place in patients who had undergone conventional and FDG-PET/CT within 1 month. 
4. Discussion 
The results of the present study show that the TNM-stage of patients with high risk breast cancer changes in up 
to 31% when an FDG-PET/CT is used instead of conventional imaging. This resulted in treatment changes in 25% 
of patients. These changes in treatment are substantial and influence the general management of patients with 
stage III or IV breast carcinoma.  
 
Table 1. Patient characteristics and diagnostic outcome before and after FDG-PET/CT.                              
Patient no. Age 
Metastases TNM stage Treatment c 
CIa FDG-PET/CT After CI After FDG-PET/CT Δb After CI After FDG-PET/CT Δ 
1 70 − + IIIC IV Yes Adj. CT/RT + surgery Pall. CT Yes 
2 61 − + IIIB IV Yes Adj. CT/RT + surgery Pall. CT Yes 
3 41 − − IIIB IIIC Yes Adj. CT/RT + surgery Adj. CT/RT + surgery Yes 
4 45 + + IV IV No Pall. CT Pall. CT No 
5 80 + + IV IV No Pall. CT Pall. CT No 
6 51 − − IIIA IIIA No Adj. CT/RT + surgery Adj. CT/RT + surgery No 
7 71 − − IIIC IIIC No Adj. CT/RT + surgery Adj. CT/RT + surgery No 
8 55 − − IIIA IIIA No Adj. CT/RT + surgery Adj. CT/Rt + surgery No 
9 84 − + IIIA IV Yes Locoregional RT Locoregional RT No 
10 55 − − IIIB IIIB No Adj. CT/RT + surgery Adj. CT/RT + surgery No 
11 42 − − IIIA IIIA No Adj. CT/RT + surgery Adj. CT/RT + surgery No 
12 33 + + IV IV No Pall. CT Pall. CT No 
13 75 + + IV IV No Pall. CT Pall. CT No 
14 55 + − IV IIIA Yes Pall. CT Adj. CT/RT + surgery Yes 
15 71 + + IV IV No Pall. CT Pall. CT No 
16 55 + + IV IV No Pall. CT Pall. CT No 
aCI = conventional imaging: the combination of liver ultrasonography, chest X-ray and bone scintigraphy; bΔ = difference; cAdj. = adjuvant; CT = 
chemotherapy; RT = radiotherapy; pall. = palliative. 
B. F. Bulten et al. 
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(a)                                     (b) 
    
(c)                                    (d) 
  
(e)                                     (f) 
Figure 1. Patient no. 2, upgraded to grade IV breast carcinoma after FDG-PET/CT. 
Chest X-ray (a) and bone scintigraphy (b) without distant metastases. Ultrasonography 
is not shown here, but did not show metastases. Maximum intensity projection (MIP, 
(c)) and axial slices of FDG-PET/CT. The axial slices show in detail axillary and me- 
diastinal lymph nodes (d), axillary lymph nodes and pulmonary metastases (arrows) (e) 
and a bone metastasis (f).                                                   
B. F. Bulten et al. 
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(a)                                         (b) 
  
(c)                                              (d) 
  
(e)                                              (f) 
 
(g) 
Figure 2. Patient no. 14, downgraded to grade III breast carcinoma after FDG-PET/CT. Chest 
X-ray (a) and bone scintigraphy (b) showed no metastases. Liver ultrasonography (c) showed 
two lesions suspect for metastases. Axial slices of the CT abdomen ((d) and (e), see arrows) 
showed the two lesions, metastasis could not be excluded. Axial slices of the FDG-PET/CT 
((f) and (g)) did not display increased uptake in those lesions, excluding metastases.           
B. F. Bulten et al. 
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The Dutch guideline for breast cancer recommends the use of FDG-PET/CT in assessing metastatic disease of 
primary grade III breast carcinoma [5]. This is based on research by several groups [3] [4] [6]-[8]. For example, 
Fuster et al. conducted a prospective study in 60 patients, showing a sensitivity of 100% and a specificity of 98% 
for FDG-PET (without CT), compared with a sensitivity of 60% and specificity of 93% in conventional imaging 
[3]. In another study by Mahner et al. in 199 patients, FDG-PET detected distant metastases with a sensitivity of 
87% and a specificity of 86%. This is far better than conventional imaging (43% and 98% respectively), but 
comparable to CT (83% and 84%) [4]. Koolen et al. recently compared FDG/PET-CT with conventional imag- 
ing in 154 patients, resulting in a sensitivity of 100%, specificity of 96%, positive predictive value of 80%, neg- 
ative predictive value of 100% and an accuracy of 97% [8].  
In all these studies more lesions are detected by FDG-PET/CT than by conventional imaging. This is not al- 
ways important for clinical issues and decision making. However, change of TNM-classification (but not stage) 
might have an impact on the clinical setting in terms of prognosis and informing patients. When additional le- 
sions result in a different TNM-stage (e.g. IIIC instead of IV), the impact on management of individual patients 
is greatly affected. In the present study the change of TNM-stage after FDG-PET/CT resulted in an adjustment 
of treatment in 25% of patients. Koolen et al. found that in 8% of cases treatment was adjusted after FDG-PET/ 
CT, but the difference between these numbers can be accounted for by the inclusion of stage III and IV breast 
carcinoma in our study (and stage II and III in Koolen’s) [8]. Furthermore, one of our patients received a cura- 
tive instead of a palliative treatment, which can be seen as a downstaging of treatment, while the patients of 
Koolen were all upstaged. For patients this is, of course, of great importance. Another study in 60 patients with 
invasive breast cancer larger than 3 cm and/or at least one tumour-positive axillary lymph node, TNM-stage was 
changed in 17% after FDG-PET/CT and 12% received an alternative radiotherapy approach [2]. Abovemen- 
tioned studies show that the introduction of FDG-PET/CT results in treatment changes, which is an important 
clinical finding. 
Additionally, the Dutch guideline recommends the use of FDG-PET/CT when local, regional or distant recur- 
rence is suspected [5]. An extensive systematic review by Pennant et al. showed a significantly higher sensitivi- 
ty and specificity for locoregional recurrence than conventional imaging, as well as a higher sensitivity in com- 
parison with CT [9]. This suggests an improved accuracy in detecting locoregional recurrence when FDG-PET/ 
CT is added to conventional imaging, also in stage II breast cancer.  
Finally, the Dutch guideline supports the use of FDG-PET/CT in equivocal lesions identified by other imag- 
ing modalities [5]. 
Interestingly, other guidelines are often reticent about the use of FDG-PET/CT in breast carcinoma. For ex- 
ample, the British guideline, published in 2009, advises to use FDG-PET/CT in equivocal lesions, but sees no 
role for FDG/PET-CT in assessment of disseminated disease. It states that assessment of visceral metastases has 
to be done by “a combination of plain radiography, ultrasound, CT and MRI” and of bone metastases in “the 
bony window of the CT or MRI or a bone scintigraphy” [10]. The exact combination or evidence for this advice 
is lacking. Furthermore, CT might not detect bone metastases at diagnosis, while FDG-uptake is already present, 
as yet known from lung cancer [11].   
The European Society of Medical Oncology does not recommend the routinely use of FDG-PET/CT as well. 
Their recently published guideline states that routine staging evaluations are directed at locoregional disease, as 
asymptomatic distant metastases are very rare and patients do not profit from comprehensive laboratory and ra- 
diological staging. They furthermore advise to use FDG-PET/CT only when conventional imaging is inconclu- 
sive [12].  
The National Comprehensive Cancer Network (NCCN) also recommends against FDG-PET/CT in their 2009 
guideline, because of high false-negative rates in detecting small (<1 cm) lesions, low sensitivity for detecting 
axillary metastases, low prior probability of the patients having distant metastatic disease and a high rate of 
false-positive scans [13]. However, modern PET/CT systems have a far better spatial resolution, especially when 
time-of-flight scanning can be performed, reducing the detection limit of FDG-avid tumors (most breast cancer) 
to 3 - 4 millimeter. The number of false-negative scans is therefore dramatically reduced. Furthermore, sensitiv- 
ity for detecting axillary metastases might be low, though still improving, but the specificity in the assessment of 
axillary lymph nodes is high (96%) [3]. When a positive lymph node is found on FDG-PET/CT, the chance of 
metastases is high and additional ultrasonography and biopsy need to be done [2]. Above that, non-axillary 
lymph nodes can be detected by FDG-PET/CT; according to Aukema et al. these are present in 28% of patients 
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with grade II or III breast carcinoma [3]. Finally, when small and non-specific FDG-positive lesions are found 
(and therefore the chance of false-positivity is high), the Dutch guideline advises to ignore these when a patient 
can still be cured [2].  
Prior probability of patients having distant disease is relatively low, as posed by NCCN. However, in the 
present study 19% of patients had distant metastases on FDG-PET/CT that were missed on conventional imag- 
ing. These patients did not have to undergo an unnecessary tough and risky therapy regimen with a mastectomy, 
lymph node dissection, radiotherapy and chemotherapy, which would have been indicated when FDG-PET/CT 
was not performed.  
5. Conclusion 
The results of the present study confirm the previously reported impact of FDG-PET/CT in staging and treat- 
ment decision making of high-risk breast cancer patients. We suggest to replace conventional imaging with 
FDG-PET/CT in the assessment of distant metastasis in this category of patients and to adopt this in national and 
international guidelines, so patients receive the treatment they deserve. 
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